Exploring the Potential of Enhanced Prognostic Performance of NCCN‐IPI in Diffuse Large B‐Cell Lymphoma by Integrating Tumor Microenvironment Markers: Stromal FOXC1 and Tumor pERK1/2 Expression. This evidence concerns the gene FOXC1 and diffuse large B-cell lymphoma.